EP4656183A1 — Tirzepatide compositions and preparation method
Assigned to Galenicum Health Slu · Expires 2025-12-03 · 0y expired
What this patent protects
The present invention relates to stable pharmaceutical compositions comprising tirzepatide, a dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. In particular, the invention provides aqueous formulations of tirzepatide co…
USPTO Abstract
The present invention relates to stable pharmaceutical compositions comprising tirzepatide, a dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. In particular, the invention provides aqueous formulations of tirzepatide containing non-inorganic buffering agents that improve chemical stability, bioavailability, and patient tolerability. The invention further encompasses pharmaceutical compositions formulated for enhanced storage stability and reduced aggregation, ensuring optimal therapeutic efficacy in the treatment of diabetes mellitus and obesity.
Drugs covered by this patent
- Mounjaro (TIRZEPATIDE) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.